三阴性乳癌市场:KOL的洞察

本报告提供全球三阴性乳癌市场相关调查，提供市场概要，以及已上市治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

三阴性乳癌的现状与今后的治疗流程

调查目的

三阴性乳癌

• 已上市药物
  • Lynparza（阿斯特捷利康/默克公司）
  • Talzena（talazoparib，辉瑞）
  • Tecentriq（atezolizumab，罗氏）
  • Keytruda（pembrolizumab，默克公司）
  • Trodelvy（sacituzumab govitecan，吉利德科学公司）
  • Enhertu（曲妥珠单抗 deruxtecan、阿斯特捷利康/第一三共）
• 正在研究药物
  • Bavencio（Avelumab，默克集团）
  • Veriparib（ABT-888，艾伯维）
  • Zezura（尼拉帕尼、葛兰素史克）
  • Picray（alpelisib，诺华）
  • Cosela（trilaciclib，G1 Therapeutics）
  • Datopotamab deruxtecan（阿斯特捷利康/第一三共）
• 影响治疗的一般未来趋势
  • 主要洞察摘要

附录

From the growing enthusiasm for a potential subcutaneous formulation of Keytruda, the cautious optimism surrounding the outcomes of Cosela's PRESERVE 2 trial, and the promising future of datopotamab deruxtecan, explore the forefront of triple-negative breast cancer (TNBC) treatment advancements. KOLs provide a comprehensive analysis on the evolving landscape of TNBC therapy, emphasizing the significant impact these developments could have on patient care and treatment outcomes. Discover how these innovations are poised to transform the TNBC treatment paradigm.

In addition to the full report, licensed users have access to the following KOL Bulletins and special reports via the attachments area.

Key brands covered in this report:

Key questions answered:

• Which drug is the treatment of choice for each patient segment, line of therapy and unique patient characteristic, and what product attributes contribute to the preference?
• How is the product perceived by the medical community in terms of efficacy, tolerability, ease of administration and other product attributes, and how does it compare with other treatment options?
• Which recently completed or ongoing clinical trials have the greatest potential to impact prescribing trends, and how will the results impact practice in the future (e.g. PERSEVERE, neoBREASTIM, OptimICE-PCT, PRESERVE 2, ASCENT-03, ASCENT-04, ASCENT-05, TROPION-Breast04, TROPION-Breast05, etc.)?
• What will a product need to show in order to become the treatment of choice in a specific line of therapy, and is it likely that the product will meet these requirements?
• How will the use of each product change in the future in terms of line of therapy and preference?
• What will the pipeline products need to show in terms of efficacy and tolerability endpoints to effectively compete with current therapies, and what is the likelihood that they will achieve those endpoints?

Table of Contents

Executive summary (9)

Triple-negative breast cancer current and future treatment algorithm (1)

Research objectives (2)

Triple-negative breast cancer (91)

• Marketed drugs (48)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.) (6)
  • Talzenna (talazoparib; Pfizer) (6)
  • Tecentriq (atezolizumab; Roche) (10)
  • Keytruda (pembrolizumab; Merck & Co.) (8)
  • Trodelvy (sacituzumab govitecan; Gilead Sciences) (10)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo) (8)
• Pipeline drugs (39)
  • Bavencio (avelumab; Merck Group) (6)
  • veliparib (ABT-888; AbbVie) (8)
  • Zejula (niraparib; GSK) (5)
  • Piqray (alpelisib; Novartis) (4)
  • Cosela (trilaciclib; G1 Therapeutics) (8)
  • datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) (8)
• General future trends impacting treatment (4)
  • Key insights summary (4)

Appendix (4)

• KOL details (4)
  • KOLs from North America (2)
  • KOLs from Europe (1)